At 6.1% CAGR, South & Central America Infusion Devices Market is Projected to be Worth US$ 1,164.42 Million by 2031, says The Insights Partners

According to The Insights Partners research, the South & Central America infusion devices market was valued at US$ 722.52 million in 2023 and is expected to reach US$ 1,164.42 million by 2031, registering a CAGR of 6.1% from 2023 to 2031. Growing technological advancements and growing geriatric population are among the critical factors attributed to driving the South & Central America infusion devices market growth.

The field of healthcare is experiencing significant technological advancements, with IV infusion systems leading the way in innovation. A few latest developments in IV infusion technology are smart pumps, wireless connectivity, electronic health record integration, and other features designed to improve operational efficiency. Smart Pump Integration: These devices are designed for precise and programmable fluid delivery, ensuring accurate dosing while ensuring patient safety. In addition to health benefits, smart pumps contribute to operational efficiency by automating and optimizing the infusion process. For example, in April 2024, Baxter announced the US FDA clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, advancing connected and intelligent infusion therapy. The Novum IQ Infusion Platform offers large volume and syringe infusion smart pumps on an integrated system with shared innovative digital health solutions to improve patient safety and efficiency for clinicians.

Remote Monitoring: The integration of wireless connectivity in IV infusion systems can transform the handling of infusion therapies. This feature enables remote monitoring and management, allowing providers to supervise multiple infusion setups from a central location. Remote monitoring technology also enhances the overall workflow within healthcare facilities and streamlines logistical aspects. Infuzamed provides a mobile, wearable infusion pump with advanced remote monitoring and control capabilities. The lightweight product eliminates the use of traditional cumbersome wires and poles. The device fits sleekly and comfortably on a patient's forearm and requires no additional attachments.

Electronic Health Records: Efficient data management is a fundamental aspect of modern healthcare, and advanced IV infusion systems integrate with electronic health records. Integration allows for streamlined documentation and administrative processes. Improved record-keeping and data accessibility contribute to enhanced operational efficiency, with positive implications for the entire healthcare system. WellSpan Health and CareFusion, a BD company, jointly announced the implementation of the Alaris System across all four WellSpan hospitals. WellSpan York Hospital is the first hospital to go live with the latest infusion device and bidirectional interoperability between the infusion device and the electronic health record.

Enhanced User Interface: User-friendly advancements and interfaces in human-machine interaction are essential to ensure the smooth operation of IV infusion systems. Also, intuitive designs contribute to the ease of use for healthcare professionals, potentially minimizing the likelihood of errors during administration. The focus is on enhancing user experience and operational proficiency without directly linking it to patient health outcomes. B. Braun offers a large-volume pump and a syringe pump with the same hardware architecture, user interface, and identical drug library and infusion management software.

Thus, the increasing technological advancements are expected to be a key trend in the South & Central America infusion devices market.

On the contrary, frequent product recalls of infusion devices hamper the growth of South & Central America infusion devices market

By product type, the South & Central America infusion devices market is bifurcated into infusion pumps and infusion sets. The infusion pumps held a 75.2% share of South & Central America infusion devices market share in 2023, amassing US$ 543.27 million. It is projected to garner US$ 887.32 million by 2031 to register 6.3% CAGR during 2023-2031.

In terms of infusion pumps, the market is segmented into volumetric pumps, syringe pumps, insulin pumps, patient control analgesia (PCA) pumps, enteral pumps, implantable pumps, and elastomeric pumps. The volumetric pumps segment held 29.0% share of South & Central America infusion devices market share in 2023, amassing US$ 157.37 million. It is projected to garner US$ 249.06 million by 2031 to register 5.9% CAGR during 2023-2031.

By infusion sets, the South & Central America infusion devices market is segmented into vented infusion sets and non-vented infusion sets. The vented infusion sets held 61.2% share of South & Central America infusion devices market share in 2023, amassing US$ 109.73 million. It is projected to garner US$ 173.51 million by 2031 to register 5.9% CAGR during 2023-2031.

By application, the South & Central America infusion devices market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes held a 37.6% share of South & Central America infusion devices market share in 2023, amassing US$ 271.57 million. It is projected to garner US$ 455.34 million by 2031 to register 6.7% CAGR during 2023-2031.

By end user, the South & Central America infusion devices market is segmented into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics held a 53.8% share of South & Central America infusion devices market share in 2023, amassing US$ 388.51 million. It is projected to garner US$ 622.54 million by 2031 to register 6.1% CAGR during 2023-2031.

Based on country, the South & Central America infusion devices market is categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 58.7% share of South & Central America infusion devices market in 2023. It was assessed at US$ 423.93 million in 2023 and is likely to hit US$ 703.53 million by 2031, registering a CAGR of 6.5% during 2023-2031.

Key players operating in the infusion devices market are B Braun SE, Baxter International Inc, Becton Dickinson and Co, BPL Medical Technologies Pvt Ltd, CODAN US Corp, Eitan Medical Ltd, Elimedical Inc, Fresenius Kabi AG, ICU Medical Inc, KD Scientific Inc, Medtronic Plc, Moog Inc, Nipro Corp, Polymedicure, Tandem Diabetes Care Inc, Terumo Corp, and Zimed Healthcare Ltd, among others.

In May-2024: Moog Inc. received US FDA 510(k) clearance for CURLIN 8000 Ambulatory Infusion System. This premium infusion platform was developed specifically for use in home infusion settings. The CURLIN 8000 combines a reliable and robust design with a simple, intuitive user interface designed for easy navigation by both clinical and non-clinical users. The CURLIN 8000 also integrates seamlessly with CURLIN RxManager, a completely new medication safety software developed to complement existing home infusion workflows.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com